KR102528435B1 - 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물 - Google Patents

신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물 Download PDF

Info

Publication number
KR102528435B1
KR102528435B1 KR1020227032048A KR20227032048A KR102528435B1 KR 102528435 B1 KR102528435 B1 KR 102528435B1 KR 1020227032048 A KR1020227032048 A KR 1020227032048A KR 20227032048 A KR20227032048 A KR 20227032048A KR 102528435 B1 KR102528435 B1 KR 102528435B1
Authority
KR
South Korea
Prior art keywords
subject
formula
pharmaceutical composition
compound
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227032048A
Other languages
English (en)
Korean (ko)
Other versions
KR20220132030A (ko
Inventor
라드코 코머스
앨빈 시
Original Assignee
트래비어 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트래비어 테라퓨틱스, 인코포레이티드 filed Critical 트래비어 테라퓨틱스, 인코포레이티드
Priority to KR1020237014470A priority Critical patent/KR20230066644A/ko
Publication of KR20220132030A publication Critical patent/KR20220132030A/ko
Application granted granted Critical
Publication of KR102528435B1 publication Critical patent/KR102528435B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227032048A 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물 Active KR102528435B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237014470A KR20230066644A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662407860P 2016-10-13 2016-10-13
US62/407,860 2016-10-13
US201662423079P 2016-11-16 2016-11-16
US62/423,079 2016-11-16
PCT/US2017/056538 WO2018071784A1 (en) 2016-10-13 2017-10-13 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
KR1020197011413A KR20190077348A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197011413A Division KR20190077348A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014470A Division KR20230066644A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물

Publications (2)

Publication Number Publication Date
KR20220132030A KR20220132030A (ko) 2022-09-29
KR102528435B1 true KR102528435B1 (ko) 2023-05-03

Family

ID=60191503

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227032048A Active KR102528435B1 (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
KR1020247036666A Pending KR20240162167A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
KR1020237014470A Ceased KR20230066644A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
KR1020197011413A Ceased KR20190077348A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247036666A Pending KR20240162167A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
KR1020237014470A Ceased KR20230066644A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
KR1020197011413A Ceased KR20190077348A (ko) 2016-10-13 2017-10-13 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물

Country Status (11)

Country Link
US (5) US20190262317A1 (enExample)
EP (2) EP3525784B1 (enExample)
JP (4) JP2019530713A (enExample)
KR (4) KR102528435B1 (enExample)
CN (5) CN114788823A (enExample)
AU (3) AU2017341825B2 (enExample)
BR (1) BR112019007576A2 (enExample)
CA (1) CA3039819A1 (enExample)
ES (1) ES3067967T3 (enExample)
MA (1) MA46524A (enExample)
WO (1) WO2018071784A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7524167B2 (ja) * 2018-10-04 2024-07-29 トラビア セラピューティクス， インコーポレイテッド Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
BR112021012226A2 (pt) 2018-12-21 2021-09-08 Travere Therapeutics, Inc. Composições de esparsentano amorfo
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
HRP20260121T1 (hr) * 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
US20230270718A1 (en) * 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
WO2022246200A1 (en) 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
KR20240051999A (ko) * 2021-08-26 2024-04-22 상하이 한서 바이오메디컬 컴퍼니 리미티드 방향족 고리 함유 생물학적 길항제, 이의 제조 방법 및 용도
WO2023127853A1 (ja) * 2021-12-28 2023-07-06 株式会社アークメディスン 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
EP4719402A1 (en) 2023-05-31 2026-04-08 Travere Therapeutics, Inc. Sparsentan for use in a method of treating iga-mediated diseases
KR20260089488A (ko) 2023-09-20 2026-06-15 트래비어 테라퓨틱스, 인코포레이티드 면역글로불린 A 신장병증(IgAN)의 치료를 위한 스파르센탄
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法
WO2026165438A1 (en) 2025-01-31 2026-08-06 Travere Therapeutics, Inc. Sparsentan for the treatment of patients post kidney transplantation with proteinuric iga nephropathy or fsgs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164865A1 (en) 2009-03-31 2015-06-18 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26984A (id) * 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001044239A2 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) * 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
PL3536685T3 (pl) * 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
JP7524167B2 (ja) 2018-10-04 2024-07-29 トラビア セラピューティクス， インコーポレイテッド Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164865A1 (en) 2009-03-31 2015-06-18 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Am. J. Physiol. Regul. Integr. Comp. Physiol., 310, R877-R884, 2016.
Biochimica et Biophysica Acta, 1802, 1203-1213, 2010.
Inter, Heart Journal, 56(6), 5865-586, 2015.

Also Published As

Publication number Publication date
CN114788823A (zh) 2022-07-26
JP2025060754A (ja) 2025-04-10
ES3067967T3 (en) 2026-05-26
KR20220132030A (ko) 2022-09-29
CA3039819A1 (en) 2018-04-19
CN117085013A (zh) 2023-11-21
KR20230066644A (ko) 2023-05-16
WO2018071784A1 (en) 2018-04-19
US20210196688A1 (en) 2021-07-01
AU2017341825B2 (en) 2023-06-01
KR20190077348A (ko) 2019-07-03
AU2017341825A1 (en) 2019-04-11
US20250325522A1 (en) 2025-10-23
US20250325523A1 (en) 2025-10-23
JP2022137245A (ja) 2022-09-21
CN110049764A (zh) 2019-07-23
US10864197B2 (en) 2020-12-15
KR20240162167A (ko) 2024-11-14
CN116983302A (zh) 2023-11-03
EP4744733A2 (en) 2026-05-20
EP3525784B1 (en) 2026-01-28
JP2022141802A (ja) 2022-09-29
EP3525784A1 (en) 2019-08-21
JP2019530713A (ja) 2019-10-24
AU2023219839A1 (en) 2023-09-07
AU2023219839B2 (en) 2025-08-21
BR112019007576A2 (pt) 2019-07-02
CN117017985A (zh) 2023-11-10
AU2025271121A1 (en) 2025-12-18
EP4744733A3 (en) 2026-07-29
US20200281901A1 (en) 2020-09-10
MA46524A (fr) 2019-08-21
US20190262317A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
US20250325522A1 (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
US11207299B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo
WO2025064688A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4